Our Management Team
The Trellis management team brings more than 100 years of expertise to the discovery and development of therapeutic antibodies, leveraging the company's proprietary platform for antibody discovery.
 |
Stote Ellsworth, President and Chief Executive Officer Stote Ellsworth has led development of Trellis' totally human antibody platform, CellSpot™, now generating a pipeline of therapeutic antibodies. Mr. Ellsworth has spent his career bringing high technology systems solutions to the life science industry. He joined Trellis in 2003 to bring to reality the company's CellSpot™ platform now responsible for generating a pipeline of totally human therapeutic antibodies directly from human blood. The platform blends life science technology in cell and molecular biology with state-of-the-art microscopy, software, and nanotechnology. Prior to Trellis, Mr. Ellsworth was the VP R&D and Chief Operating Officer at First Medical, a point-of-care cardiac diagnostic company acquired by Sigma in 2000. This was preceded by a role as Vice President of Engineering at Becton Dickinson where he was responsible for developing through commercial release numerous flow cytometry products which now dominate that market. He holds a degree in Bioscience Technology from the University of California Santa Cruz, a BA from Dartmouth in Engineering and Mathematics, and an MS in Electrical Engineering from Stanford University. |
 |
Lawrence Kauvar, PhD, Founder and Senior Vice President Larry Kauvar has built a 20-year reputation as an inventor of innovative platform technologies. Dr. Kauvar is an entrepreneur and scientist who founded Trellis and was previously the founder and Chief Scientific Officer of Telik, a small molecule drug company focused on oncology. He holds 40 US patents for methods, tools and drug compounds and is one of the inventors of CellSpot™, Trellis' core technology. Dr. Kauvar holds a PhD from Yale in Molecular Biophysics and Biochemistry, did his postdoctoral studies at Caltech and holds an undergraduate degree from Harvard University. |
 |
Bill Usinger, PhD, Vice President R&D Bill Usinger has extensive experience in therapeutic antibody discovery and development and has generated and characterized antibodies for use in a broad variety of research and immunoassay applications. Dr. Usinger is a project leader, inventor and entrepreneur with expertise in drug development, assay development and validation, and technology evaluation and licensing. Dr. Usinger was the Founder and President of Immusine Labs and Cofounder and Vice President of R&D of Metabolex Corporation. For the past 12 years, Bill has worked in the field of monoclonal antibody discovery and development and served as the Department Head of ImmunoBiology at FibroGen and as Research Director in the Department of Biotherapeutics at Chiron/Novartis. Dr. Usinger received his Ph.D. from the University of Wisconsin (Immunology) and studied vaccine immunomodulators during his Post Doctoral fellowship at UC Berkeley. Dr. Usinger has more than 55 publications and holds numerous US patents and applications. |
 |
Jack M. Anthony Jack Anthony brings extensive business development and biotech transaction experience from roles with Symphogen, Saegis, Tularik, and FibroGen. Jack M. Anthony has been CEO/CBO of a number of San Francisco Bay Area biotechnology companies including Osprey USA, Pharmix, Saegis, Tularik, FibroGen, Inhale and AIS. Jack began his life sciences career at Baxter Healthcare Corporation and for seventeen years held various sales, marketing and general management positions in the U.S. and internationally. He departed Baxter as a Vice President of the Blood Therapy Group. Jack has a BS in Biology from Allegheny College and served as a Navy officer for five years. Jack also founded BioMentorz™ in 2006, a business development consultancy which specializes in the biotechnology sector. |